Clinical Trial Update: Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating gemcitabine, carboplatin, and veliparib (ABT-888) in refractory testicular germ cell cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Testicular Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute, Slovakia | Conditions: Testicular Cancer | Phase 2 | Status: COMPLETED